Raymond James analyst Timur Ivannikov downgraded Neximmune to Market Perform from Outperform without a price target. The analyst cites the company’s strategic program re-alignment for the downgrade and says he needs to see additional data from the AIM INJ platform in order to get more constructive on the shares. NexImmune is pausing enrollment in adoptive cell therapy studies and seeking external partnerships for NEXI-001 and NEXI-003, Ivannikov tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEXI: